8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549  

FORM 8-K  

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 5, 2022

BIOXYTRAN, INC.

(Exact Name if Business Issuer as specified in its Charter) 

Nevada	001-35027	26-2797630
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

75, Second Avenue, 
Suite 605

Needham MA, 02494

(Address of principal executive offices, including zip code)

(617) 494-1199

(Registrant’s telephone number including area code) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 1 4a- 12 under the Exchange Act (17 CFR 240.1 4a- 12)

☐ Pre-commencement communications pursuant to Rule 1 4d-2(b) under the Exchange Act (17 CFR 240.1 4d-2(b))

☐ Pre-commencement communications pursuant to Rule 1 3e-4(c) under the Exchange Act (17 CFR 240.1 3e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	BIXT	OTC Pink

Item 1.01. Entry into a Material Definitive Agreement.

Between January 5^th and 10^th, 2022, Bioxytran, Inc. (“Bioxytran” or the “Company”) entered into 34 Note Purchase Agreements (the “Agreements”) with accredited investors for the issuance of a total principal amount of $1,467,000 in 1-year convertible notes (the “Notes”). The Notes carry an interest rate of 6% and are convertible into shares of the Company’s Common Stock at a fixed price of $0.25. The Agreements and the Notes were approved by the Company’s Board of Directors on January 10, 2022. The Notes contain an aggregate discount of $128,290. The discount resulted in the Company receiving a total of $86,040 less in cash and making up the remainder of the discount by issuing 264,060, 5-year warrants with an exercise price of $0.25 (the “Warrants”), currently valued at $0.16 based on the Black Scholes Option Pricing Model. The Cash and the Warrants were issued to a sole Placement Agent: WallachBeth Capital (Member FINRA / SIPC).

Debtor	Date of Issuance		Principal Amount		Commission & Fees		Warrants Issued		Term		Exercise Price		Amortization of Warrants		Maturity
34 Notes		01/10/2022	$	1,467,000	$	—		—		—	$	—	$	—	01/10/2023
Agent		01/10/2022				86,040		264,060		5		0.25		42,250
			$	1,467,000	$	86,040		264,060					$	42,250

Item 3.02 Unregistered Sales of Equity Securities

The information provided in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

Item 8.01. Other Events

On January 12, 2022, Bioxytran released a corporate presentation explaining the current state of the Company’s pharmaceutical development. The presentation is attached hereto as Exhibit 99.1 hereto.

1 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
Number	Description
10.67	Form of Convertible Note, dated January 5, 2022.
10.68	Form of Note Purchase Agreement, dated January 5, 2022.
99.1	Bioxytran, Inc. Corporate Presentation, dated January 12, 2022

2 

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

By:	/s/ David Platt
Name:	Dr. David Platt
Title:	President and Chief Executive Officer
Dated:  January 14, 2022

3 

EX-10.67

Exhibit 10.67

THIS NOTE AND THE SHARES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT.

BIOXYTRAN, INC.
CONVERTIBLE NOTE

Issuance Date: January      , 2022 Original Principal Amount: $                   

FOR VALUE RECEIVED, Bioxytran, Inc., a Nevada corporation (“Company”) hereby promises to pay to or upon the order of                      , or his registered assigns or successors-in-interest (the “Holder”) the principal sum of                                     Dollars ($                 ), together with all accrued but unpaid interest thereon, if any, on the Final Maturity Date, to the extent such principal amount and interest have not been repaid or converted into shares of the Company’s Common Stock, $0.001 par value, (the “Common Stock”), in accordance with the terms hereof. Interest on the unpaid principal balance hereof shall accrue at the rate of 6% per annum from the date of original issuance hereof (the “Issuance Date”) until the Final Maturity Date, or such earlier date upon acceleration or by conversion, repayment or redemption in accordance with the terms hereof. Interest on this Note shall accrue daily commencing on the Issuance Date, shall be paid at the Final Maturity Date and shall be computed on the basis of a 360-day year, 30-day months and actual days elapsed and shall be payable in accordance with Section 2 hereof. Notwithstanding anything contained herein, this Note shall bear interest on the outstanding Principal Amount from and after the occurrence and during the continuance of an Event of Default, at the rate (the “Default Rate”) equal to the lower of eighteen percent (18%) per annum or the highest rate permitted by applicable law. Unless otherwise agreed or required by applicable law, payments will be applied first to any unpaid collection costs, then to unpaid interest and fees and any remaining amount to unpaid principal.

All payments of principal of and interest on this Note shall be made in lawful money of the United States of America by wire transfer of immediately available funds to such account as the Holder may from time to time designate by written notice in accordance with the provisions of this Note. This Note may not be prepaid in whole or in part except as specifically provided herein. Whenever any amount expressed to be due by the terms of this Note is due on any day which is not a Business Day (as defined below), the same shall instead be due on the next succeeding day which is a Business Day and such extension shall be taken into account in determining the amount of interest accrued on this Note.

1 

The following terms and conditions shall apply to this Note:

1. Definitions.

(a) Capitalized terms used herein and not otherwise defined herein shall have the meanings set forth in the Purchase Agreement.

(b) For purposes hereof the following terms shall have the meanings ascribed to them below:

“Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 144 under the Securities Act of 1933, as amended.

“Bankruptcy Event” means any of the following events: (a) the Company or any material subsidiary commences a case or other proceeding under any bankruptcy, reorganization, arrangement, adjustment of debt, relief of debtors, dissolution, insolvency or liquidation or similar law of any jurisdiction relating to the Company or any material subsidiary thereof; (b) there is commenced against the Company or any material subsidiary any such case or proceeding that is not dismissed within 60 days after commencement; (c) the Company or any material subsidiary thereof is adjudicated insolvent or bankrupt or any order of relief or other order approving any such case or proceeding is entered; (d) the Company or any material subsidiary suffers any appointment of any trustee, custodian or the like for it or any substantial part of its property that is not discharged or stayed within 60 days; (e) the Company or any material subsidiary makes a general assignment for the benefit of creditors; (f) the Company or any material subsidiary fails to pay, states that it is unable to pay, or is unable to pay, its debts (excluding those reasonably disputed in good faith by the Company in the case of failure to pay and for which it has reserves on its books and financial statements) generally as they become due; (g) the Company or any material subsidiary calls a meeting of its creditors with a view to arranging a composition, adjustment or restructuring of its debts; or (h) the Company or any material subsidiary, by any act or failure to act, expressly indicates its consent to, approval of or acquiescence in any of the foregoing or takes any corporate or other action for the purpose of effecting any of the foregoing.

“Cash” or “cash” means at any time such coin or currency of the United States of America as shall at such time be legal tender for the payment of public and private debts.

“Company Notice Date” shall have the meaning provided in Section 2(c).

“Conversion Date” shall have the meaning provided in Section 3(b).

“Conversion Price” means $0.25, subject to adjustment as set forth herein.

“Event of Default” shall have the meaning provided in Section 4(a).

“Exchange Act” means the Securities Exchange Act of 1934, as amended.

“Final Maturity Date” means August 31, 2022.

“Holder Share Notice” shall mean a written notice by Holder of its intent to convert the Note to common stock.

2 

“Conversion Notice” shall have the meaning provided in Section 3(a).

“Principal Amount” means at any time the sum of (i) the outstanding principal amount of this Note at such time, (ii) all accrued but unpaid interest hereunder to such time, and (iii) any default payments owing at such time to the Holder under the Note but not theretofore paid or added to the Principal Amount.

“SEC” means the United States Securities and Exchange Commission. “Securities Act” means the Securities Act of 1933, as amended.

“Underlying Shares” means the shares of Common Stock issued or issuable upon conversion of, in lieu of cash payment of principal of, or interest on, as repayment of principal under, or otherwise pursuant to, this Note in accordance with the terms hereof.

Section 2. Payments of Principal and Interest.

(a)  Interest. The Company shall pay interest accruing on this Note (from the date hereof or the date of actual receipt of the proceeds of the loan) on all principal outstanding at the Interest Rate, on the Final Maturity Date

(b)  Principal. The entire Principal Amount of this Note, plus any and all default payments owing under the Note but not previously paid, shall become due and payable on the Final Maturity Date. Any principal of this Note that is converted pursuant to Section 3 shall be applied to reduce the principal payable under this Section 2(b). The Company may not prepay or convert this Note without the Holder’s consent.

Section 3. Conversion.

(a)  Conversion Rights. Upon the terms and subject to the conditions hereof, the Holder shall have the right, at the Holder’s option, to convert the outstanding Principal Amount and accrued and unpaid interest thereon into Common Stock, in whole at any time or in part from time to time, by delivering to the Company a duly executed notice of conversion in the form attached hereto as Exhibit A (the “Conversion Notice”), which may be transmitted by telephone line facsimile transmission.

(b) Common Stock Issuance Upon Conversion.

(i)   Conversion Procedures. Upon any conversion of this Note pursuant to Section 3(a) above, the outstanding Principal Amount being converted and accrued and unpaid interest thereon to the applicable Conversion Date shall be converted into such number of fully paid, validly issued and non-assessable shares of Common Stock, free of any liens, claims and encumbrances, as is determined by dividing the outstanding Principal Amount being converted and accrued and unpaid interest thereon to the applicable Conversion Date by the then applicable Conversion Price. The date of any Conversion Notice hereunder shall be referred to herein as the “Conversion Date”. If a conversion under this Note cannot be effected in full for any reason, or if the Holder is converting less than all of the outstanding Principal Amount hereunder pursuant to a Conversion Notice, the Company shall, upon request of the Holder, promptly deliver to the Holder a new Note having a Principal Amount equal to the amount of such outstanding Principal Amount as has not been

3 

converted. The Holder shall not be required physically to surrender this Note to the Company upon any conversion unless the full outstanding Principal Amount of this Note is being converted or repaid. The Holder and the Company shall maintain records showing the outstanding Principal Amount so converted and repaid and the dates of such conversions or repayments or shall use such other method, reasonably satisfactory to the Holder and the Company, so as not to require physical surrender of this Note upon each such conversion or repayment. The Holder agrees that, if the outstanding Principal Amount of this Note is less than the Principal Amount stated on the face of this Note, the Holder will not voluntarily transfer this Note at any time when no Event of Default has occurred and is continuing without first surrendering this Note to the Company for issuance, without charge to the Holder, of a replacement instrument that reflects the outstanding Principal Amount of this Note. The Company will deliver such replacement instrument to the Holder as promptly as practical, but in no event later than three days, after surrender by the Holder.

(ii)   Stock Certificates.  The Company will deliver to the Holder not later than three days after a particular Conversion Date, a certificate or certificates, for the number of shares of Common Stock issuable upon such conversion of this Note.

(iii)   Liability for Late Delivery. If in any case the Company shall fail to issue and deliver the shares of Common Stock to the Holder pursuant to this Note on the due date therefor, in addition to any other liabilities the Company may have hereunder and under applicable law the Company shall pay or reimburse the Holder on demand for all out-of-pocket expenses, including, without limitation, reasonable fees and expenses of legal counsel, incurred by the Holder as a result of such failure, so long as the Holder shall have given the Company a Holder Share Notice with respect to such shares of Common Stock.

(c) Conversion Price Adjustments.

(i) Stock Dividends, Splits and Combinations. In the event that the Company shall (A) pay a dividend or make a distribution to all its stockholders, in shares of Common Stock, on any class of capital stock of the Company or any subsidiary which is not directly or indirectly wholly owned by the Company, (B) split or subdivide its outstanding Common Stock into a greater number of shares, or (C) combine its outstanding Common Stock into a smaller number of shares, then in each such case the Conversion Price in effect immediately prior thereto shall be adjusted so that the Holder of this Note thereafter surrendered for conversion shall be entitled to receive the number of shares of Common Stock that such Holder would have owned or have been entitled to receive after the occurrence of any of the events described above had this Note been fully converted immediately prior to the occurrence of such event. An adjustment made pursuant to this Section 3(c)(i) shall become effective immediately after the close of business on the record date in the case of a dividend or distribution and shall become effective immediately after the close of business on the effective date in the case of such subdivision, split or combination, as the case may be. Any shares of Common Stock issuable in payment of a dividend shall be deemed to have been issued immediately prior to the close of business on the record date for such dividend for purposes of calculating the number of outstanding shares of Common Stock under clause (ii)below.

(ii)   Issuance of Common Stock or Convertible Debt. In the event that the Company shall issue or sell any shares of Common Stock for a consideration per share less than a price equal to the Conversion Price or issue or sell any Convertible Debt with a conversion price less than a price equal to the Conversion Price in effect immediately prior to such issuance or sale (the foregoing a

4 

“Dilutive Issuance”), then, immediately after such Dilutive Issuance, the Conversion Price then in effect shall be reduced to an amount equal to the consideration per share or conversion price of the Dilutive Issuance.

(iii)   Rounding of Adjustments. No adjustment in the Conversion Price shall be required unless the adjustment would require an increase or decrease of at least 1% in the Conversion Price then in effect; provided, however, that any adjustments that by reason of this Section 3(c) are not required to be made shall be carried forward and taken into account in any subsequent adjustment. All calculations under this Section 3 or Section 2 shall be made to the nearest cent or nearest 1/100th of a share.

(iv)   Notice of Adjustments. Whenever the Conversion Price is adjusted pursuant to this Section 3(c), the Company shall promptly deliver to the Holder a notice setting forth the Conversion Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment, provided that any failure to so provide such notice shall not affect the automatic adjustment hereunder.

(v) Notice of Certain Events. If:

A.             the Company shall declare a dividend (or any other distribution) on its Common Stock; or

B.             the Company shall declare a special nonrecurring cash dividend on or a tender offer for, offer to purchase or redemption of its Common Stock; or

C.             the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights; or

D.             the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock of the Company, any consolidation, amalgamation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, of any compulsory share of exchange whereby the Common Stock is converted into other securities, cash or property; or

E.             the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company; or

F.             there exists an agreement to which the Company is a party or by which it is bound providing for a Change in Control Transaction, or a Change in Control Transaction has occurred; then the Company shall cause to be filed at each office or agency maintained for the purpose of conversion of this Note, and shall cause to be mailed to the Holder at its last address as it shall appear upon the books of the Company, on or prior to the date notice of such matter to the Company’s stockholders generally is given, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, tender offer, offer to purchase, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of Common Stock of record to be entitled to such dividend, distributions, tender offer, offer to purchase, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, amalgamation, merger, sale, transfer, share exchange or Change in Control

5 

Transaction is expected to become effective or close, and the date as of which it is expected that holders of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, amalgamation, merger, sale, transfer, share exchange or Change in Control Transaction.

(v) Restrictions on Conversion. Under no circumstances may either Holder or Company effect a conversion if, after giving effect to such conversion upon delivery of shares of Common Stock, Holder would beneficially own in excess of 4.99% of the Common Stock of Company outstanding immediately after giving effect to such conversion. For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon the conversion with respect to which the determination of such sentence is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (A) conversion of the remaining, nonconverted portion of this Note beneficially owned by the Holder or any of its Affiliates and (B) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Notes or the Warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding sentence, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange. To the extent that the limitation contained in this section applies, the determination of whether this Note is convertible (in relation to other securities owned by the Holder) and of which a portion of this Note is convertible shall be in the sole discretion of Holder. To ensure compliance with this restriction, Holder will be deemed to represent to the Company each time it delivers a Notice of Conversion that such Notice of Conversion has not violated the restrictions set forth in this paragraph and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company's most recent quarterly or annual reports, (y) a more recent public announcement by the Company including on the OTC Markets website, or (z) any other notice by the Company or the Company's Transfer Agent approved by the Company setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of the Holder, the Company shall within two business days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Note, by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The provisions of this Section 3(c)(v) may be waived by the Holder, at the election of the Holder, upon not less than 61 days' prior notice to the Company, and the provisions of this Section 3(c)(v) shall continue to apply until such 61st day (or such later date, as determined by the Holder, as may be specified in such notice of waiver). The provisions of this paragraph shall be implemented in a manner necessary to preserve the intended 4.99% beneficial ownership limitation herein contained and shall not be modified in a manner otherwise than in strict conformity with the terms of this Section 3(c)(v) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended 4.99% beneficial ownership limitation herein contained or to make changes or

6 

supplements necessary or desirable to properly give effect to such 4.99% limitation. The limitations contained in this paragraph shall apply to a successor holder of this Note.

(d)  Reservation and Issuance of Underlying Securities. The Company covenants that it will at all times reserve from its authorized and unissued Common Stock a sufficient number of shares solely for the purpose of issuance upon conversion in full of this Note, free from preemptive rights or any other actual contingent purchase rights of persons other than the Holder. The Company represents, warrants and covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid, and nonassessable.

(e)  No Fractions. Upon a conversion hereunder the Company shall not be required to issue stock certificates for a fraction of a share of Common Stock. The Holder shall be entitled to receive, in lieu of the fraction of a share, one whole share of Common Stock.

(f)   Charges, Taxes and Expenses. Issuance of shares of Common Stock upon the conversion of this Note shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such shares, all of which taxes and expenses shall be paid by the Company, and such shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event certificates for shares of Common Stock are to be issued in a name other than the name of the Holder, the applicable Conversion Notice, when given for such conversion shall be accompanied or followed by an assignment form for the applicable portion of this Note or such shares, as the case may be; and provided further, that the Company shall not be required to pay any tax or taxes which may be payable in respect of any such transfer.

(g)  Cancellation. After the entire Principal Amount (including accrued but unpaid interest and default payments at any time owed on this Note) has been paid in full or converted into Common Stock, this Note shall automatically be deemed canceled and the Holder shall promptly surrender this Note to the Company at the Company’s principal executive offices; provided, however, that the failure to surrender this Note shall not delay or limit such cancellation.

(h)   Notice Procedures. Any and all notices or other communications or deliveries to be provided by the Holder under this Note, including, without limitation, any Conversion Notice, shall be in writing and delivered personally, by confirmed facsimile, or by a nationally recognized overnight courier service to the Company at the facsimile telephone number or address of the principal place of business of the Company as set forth in, or provided pursuant to, the Purchase Agreement. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by facsimile, or by a nationally recognized overnight courier service addressed to the Holder at the facsimile telephone number or address of the Holder appearing on the books of the Company, or if no such facsimile telephone number or address appears, at the principal place of business of the Holder. Any notice or other communication or deliveries hereunder shall be deemed delivered (i) upon receipt, when delivered personally, (ii) when sent by facsimile, upon receipt if received on a Business Day prior to 5:00 p.m. (New York Time), or on the first Business Day following such receipt if received on a Business Day after 5:00 p.m. (New York Time) or on a day that is not a Business Day or (iii) upon receipt, when deposited with a nationally recognized overnight courier service.

7 

Section 4. Defaults and Remedies.

(a)  Events of Default. An “Event of Default” is: (i) a failure to pay any Principal Amount of this Note when due, whether at the Final Maturity Date or otherwise, (ii) a failure to pay any interest due on this Note on the date such payment is due, which failure continues for two Business Days (or ten Business Days if the Company can prove that funds were in fact wired from the Company’s account by the due date); (iii) a failure timely to issue Underlying Shares upon and in accordance with terms hereof, which failure continues for ten Business Days after the Company has received written notice from the Holder informing the Company that it has failed to issue shares or deliver stock certificates prior to the fifth Business Day following the applicable Conversion Date; (iv) failure by the Company for 20 days after written notice has been received by the Company from the Holder to comply with any material provision (other than as provided in the immediately preceding clauses (i), (ii) and (iii)) of any of this Note; (v) a material breach by the Company of its representations or warranties in this Note that continues for 10 days after written notice to the Company; (vi) any default after any cure period under, or acceleration prior to maturity of, any note, mortgage, indenture or instrument under which there may be issued or by which there may be secured or evidenced any indebtedness for money borrowed by the Company for in excess of $1 million, or for money borrowed the repayment of which is guaranteed by the Company for in excess of $1 million, whether such indebtedness or guarantee now exists or shall be created hereafter; (vii) if the Company is subject to any Bankruptcy Event; or (ix) any material provisions of the Note shall at any time and for any reason be declared by a court of competent jurisdiction to be null and void, or the Company or any Subsidiary of the Company shall repudiate or deny any portion of its liabilities or obligations thereunder.

(b)  Remedies. If an Event of Default occurs and is continuing, the Holder may declare all of the then outstanding Principal Amount of this Note, and any accrued and unpaid interest thereon, to be due and payable immediately in cash, except that in the case of an Event of Default arising from events described in clauses (vi) and (vii) of Section 4(a), this Note shall become automatically due and payable without further action or notice, and the Holder may exercise all other rights and remedies available at law or in equity. In any event the Company shall pay interest on such amount in cash at the Default Rate to the Holder if such amount is not paid within one Business Day after such acceleration. The remedies under this Note shall be cumulative.

Section 5. Certain Covenants; General.

(a)  Payment of Expenses. The Company agrees to pay all charges and expenses, including attorneys’ fees and expenses, which may be incurred by the Holder in seeking to enforce this Note.

(b)  Savings Clause. In case any provision of this Note is held by a court of competent jurisdiction to be excessive in scope or otherwise invalid or unenforceable, such provision shall be adjusted rather than voided, if possible, so that it is enforceable to the maximum extent possible, and the validity and enforceability of the remaining provisions of this Note will not in any way be affected or impaired thereby. In no event shall the amount of interest paid hereunder exceed the maximum rate of interest on the unpaid principal balance hereof allowable by applicable law. If any sum is collected in excess of the applicable maximum rate, the excess collected shall be applied to reduce the principal debt. If the interest actually collected hereunder is still in excess of the

8 

applicable maximum rate, the interest rate shall be reduced so as not to exceed the maximum allowable under law.

(c)  Amendment. Neither this Note nor any term hereof may be amended, waived, discharged or terminated other than by a written instrument signed by the Company and Holder.

(d)  Assignment, Etc. The Holder may assign or transfer this Note, subject to compliance with applicable securities laws, without the consent of the Company. The Holder shall notify the Company of any such assignment or transfer promptly. The Company may not assign its rights or obligations under this Note. This Note shall be binding upon the Company and its successors and shall inure to the benefit of the Holder and its successors and permitted assigns.

(e)  No Waiver. No failure on the part of the Holder to exercise, and no delay in exercising any right, remedy or power hereunder shall operate as a waiver thereof, nor shall any single or partial exercise by the Holder of any right, remedy or power hereunder preclude any other or future exercise of any other right, remedy or power. Each and every right, remedy or power hereby granted to the Holder or allowed it by law or other agreement shall be cumulative and not exclusive of any other, and may be exercised by the Holder from time to time.

(f) Governing Law; Jury Trial.

(i)   Governing Law. THIS NOTE WILL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEVADA WITHOUT REGARD TO ANY CONFLICTS OF LAWS PROVISIONS THEREOF THAT WOULD OTHERWISE REQUIRE THE APPLICATION OF THE LAW OF ANY OTHER JURISDICTION. THE COURTS IN NEVADA SHALL BE THE SOLE JURISDICTION WITH RESPECT TO ANY DISPUTES RELATED TO THIS NOTE

(ii) NO JURY TRIAL. The Company knowingly and voluntarily waives any and all rights it may have to a trial by jury with respect to any litigation based on, or arising out of, under, or in connection with, this Note.

(g)  Replacement Notes. This Note may be exchanged by Holder at any time and from time to time for a Note or Notes with different denominations representing an equal aggregate outstanding Principal Amount, as reasonably requested by Holder, upon surrendering the same. No service charge will be made for such registration or exchange. In the event that Holder notifies the Company that this Note has been lost, stolen or destroyed, a replacement Note identical in all respects to the original Note (except for registration number and Principal Amount, if different than that shown on the original Note), shall be issued to the Holder, without requirement for any surety bond, provided that the Holder executes and delivers to the Company an agreement reasonably satisfactory to the Company to indemnify the Company from any loss incurred by it in connection with this Note.

9 

IN WITNESS WHEREOF, the Company has caused this Note to be duly executed on the day and in the year first above written.

BIOXYTRAN, INC.

By:

Name:

Title:

Acknowledged and agreed:

HOLDER

By:

Name:

Title:

10 

ASSIGNMENT

For value received                            hereby sell(s), assign(s) and transfer(s) unto                        (Please insert social security or other Taxpayer Identification Number of assignee:                  ) the within Note, and hereby irrevocably constitutes and appoints                                   attorney to transfer the said Note on the books of BIOXYTRAN, INC., a Nevada corporation (the “Company”), with full power of substitution in the premises.

HOLDER 

By:

Name:

Title:

Date:

11 

EXHIBIT A

FORM OF CONVERSION NOTICE

(To be executed by the Holder in order to convert Convertible Note Due January     , 2023)

Re: Convertible Note issued by BIOXYTRAN, INC. identified below (the “Note”)

The undersigned hereby elects to convert the outstanding Principal Amount (as defined in the Note) indicated below of the Note into shares of Common Stock, of BIOXYTRAN, INC., a Nevada corporation (the “Company”), according to the terms hereof and of the Note, as of the date written below. If shares are to be issued in the name of a person other than undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company in accordance therewith. No fee will be charged to the Holder for any conversion, except for such transfer taxes, if any.

Conversion information:

Holder

Conversion Date

Principal Amount of Note Being Converted

Number of Shares of Common Stock to Be Issued

Applicable Conversion Price

Signature

Name

Address

12 

EX-10.68

Exhibit 10.68

NOTE PURCHASE AGREEMENT

This NOTE PURCHASE AGREEMENT (this “Agreement”) is dated as of                     , 2021 and is made by and between Bioxytran, Inc., a Nevada corporation (the “Company”), and the investors named on the signature pages hereto (the “Investors”).

WHEREAS, the Company has offered to certain accredited investors (as defined in Regulation D under the Securities Act of 1933, as amended) the Company’s Convertible Notes (the “Notes”);

WHEREAS, each Investor has agreed pursuant to such Principal Balance of Notes set forth therein in accordance with the terms, subject to the conditions, and in reliance on, the recitals, representations, warranties, covenants and agreements set forth herein.

NOW THEREFORE, in consideration of the mutual covenants, conditions and agreements herein contained, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows:

1.           Purchase and Sale of Notes. Subject to the terms and conditions set forth in this Section 1 and elsewhere in this Agreement, each Investor has agreed to purchase from the Company, and the Company has agreed to sell to such Investor, at the Closing (as defined below) the Principal Balance of Notes set forth on the Investor’s signature page.

2.           Closing; Deliveries. Subject to the satisfaction of the initial closing conditions (as set forth below), the initial closing (the “Initial Closing”) of the purchase and sale of the Notes shall take place on the date hereof. At one or more subsequent closings (each, a “Subsequent Closing,” and together with the Initial Closing, a “Closing”), the Company may sell additional Notes to additional Investors.

At each Closing, (i) each Investor who shall purchase Notes hereunder shall deliver or shall have previously delivered to the Company cash, wire transfer or a certified check in an amount equal to 100% of the principal amount subscribed for by such Investor, together with an executed signature page to this Agreement, and (ii) the Company shall issue and deliver to each Investor an executed Note in the Principal Balance purchased by such Investor in substantially the form set forth at Exhibit A hereto. Each Closing shall take place at the principal executive offices of the Company or at such other place or time as the Company may specify.

3.           Representations, Warranties and Covenants of Company. The Company represents and warrants to the Investors that as of the date hereof:

a.           Corporate Existence and Power. (i) The Company is a corporation, duly organized, validly existing and in good standing under the laws of the state of Delaware; (ii) the Company has the power and authority to conduct its business in the manner in which it is currently being conducted; and (iii) the Company has the power and authority to execute, deliver and perform this Agreement and the Notes (collectively, the “Transaction Documents”) and to sell and issue the Notes hereunder.

b.           Valid and Binding Agreement. The execution, delivery and performance of each Transaction Document have been duly authorized by all requisite action of the Company, and each Transaction Document constitutes a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms. The execution, delivery and performance of this Agreement and the other Transaction Documents by the Company does not and, to the knowledge of the Company, will not: (i) conflict with, or violate any provision of, statute, law, rule, regulation, order, judgment, injunction, decree or award of any arbitrator or governmental authority having applicability to the Company or its business, assets, or properties, or any provision of its certificate of incorporation, bylaws or similar governing instruments or (ii) conflict with, violate, or result in any breach of, or constitute a default under, any agreement or instrument to which the Company is now a party or by which the Company or any of its properties or assets may be bound or affected.

4. Representations and Warranties of the Investors.

a.    Purchase Entirely for Own Account. The Investor acknowledges that this Note is made with the Investor in reliance upon the Investor’s representation to the Company, which the Investor hereby confirms by executing this Note, that this Note and the Conversion Shares (collectively, the “Securities”) will be acquired for investment for the Investor’s own account, not as a nominee or agent (unless otherwise specified on the Investor’s signature page hereto), and not with a view to the resale or distribution of any part thereof, and that the Investor has no present intention of selling, granting any participation in, or otherwise distributing the same. By executing this Note, the Investor further represents that the Investor does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to the Securities. If other than an individual, the Investor also represents it has not been organized solely for the purpose of acquiring the Securities.

b.    Disclosure of Information; Non-Reliance. The Investor acknowledges that it has received all the information it considers necessary or appropriate to enable it to make an informed decision concerning an investment in the Securities. The Investor further represents that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the Securities. The Investor confirms that the Company has not given any guarantee or representation as to the potential success, return, effect or benefit (either legal, regulatory, tax, financial, accounting or otherwise) of an investment in the Securities. In deciding to purchase the Securities, the Investor is not relying on the advice or recommendations of the Company and has made its own independent decision that the investment in the Securities is suitable and appropriate for the Investor. The Investor understands that no federal or state agency has passed upon the merits or risks of an investment in the Securities or made any finding or determination concerning the fairness or advisability of this investment.

c.   Investment Experience. The Investor is an investor in securities of companies in the development stage and acknowledges that it is able to fend for itself, can bear the economic risk of its investment and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the Securities.

d.   Accredited Investor. The Investor is an “accredited investor” within the meaning of Regulation D promulgated under the Securities Act. The Investor agrees to furnish any additional information requested by the Company or any of its affiliates to assure compliance with applicable U.S. federal and state securities laws in connection with the purchase and sale of the Securities.

e.   Restricted Securities. The Investor understands that the Securities have not been, and will not be, registered under the Securities Act or state securities laws, by reason of specific exemptions from the registration provisions thereof which depend upon, among other things, the bona fide nature of the investment intent and the accuracy of the Investor’s representations as expressed herein. The Investor understands that the Securities are “restricted securities” under U.S. federal and applicable state securities laws and that, pursuant to these laws, the Investor must hold the Securities indefinitely unless they are registered with the Securities and Exchange Commission and registered or qualified by state authorities, or an exemption from such registration and qualification requirements is available. The Investor acknowledges that the Company has no obligation to register or qualify the Securities for resale and further acknowledges that, if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Securities, and on requirements relating to the Company which are outside of the Investor’s control, and which the Company is under no obligation, and may not be able, to satisfy.

f.  No Public Market. The Investor understands that no public market now exists for the Securities and that the Company has made no assurances that a public market will ever exist for the Securities.

g.   No General Solicitation. The Investor, and its officers, directors, employees, agents, stockholders or partners have not either directly or indirectly, including through a broker or finder solicited offers for or offered or sold the Securities by means of any form of general solicitation or general advertising within the meaning of Rule 502 of Regulation D under the Securities Act or in any manner involving a public offering within the meaning of Section 4(a)(2) of the Securities Act. The Investor acknowledges that neither the Company nor any other person offered to sell the Securities to it by means of any form of general solicitation or advertising within the meaning of Rule 502 of Regulation D under the Securities Act or in any manner involving a public offering within the meaning of Section 4(a)(2) of the Securities Act.

5.            Limitations on Disposition. Without in any way limiting the representations set forth above, each Investor agrees not to make any disposition of all or any portion of the applicable Notes unless and until (i) there is then in effect an effective registration statement under the Securities Act of 1933, as amended (the “Securities Act”), covering such proposed disposition and such disposition is made in accordance with such registration statement; or (ii) an exemption to registration under the Securities Act and applicable state securities laws is available. Each Investor further understands and agrees that, until so registered or transferred pursuant to the provisions of Rule 144 under the Securities Act, the Notes, whether upon initial issuance or upon any transfer thereof, shall bear a legend, prominently stamped or printed thereon, reading substantially as follows:

“THIS SECURITY HAS NOT BEEN REGISTERED, AND THE ISSUER HEREOF DOES NOT INTEND TO REGISTER THIS SECURITY, UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR

THE SECURITIES OR BLUE SKY LAWS OF ANY STATE AND, UNLESS SO REGISTERED, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS AND, IF REQUESTED BY THE ISSUER HEREOF, UPON DELIVERY TO THE ISSUER HEREOF OF AN OPINION OF COUNSEL (SATISFACTORY TO THE ISSUER HEREOF) TO THE EFFECT THAT SUCH TRANSFER IS EXEMPT FROM REGISTRATION UNDER (OR OTHERWISE IN COMPLIANCE WITH) THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAW.

THE ISSUER OF THIS SECURITY IS NOT OBLIGATED TO RECOGNIZE ANY SALE OR OTHER TRANSFER OF THIS SECURITY OR ANY BENEFICIAL INTEREST HEREIN MADE OTHER THAN IN ACCORDANCE WITH THE PREVIOUS PARAGRAPH. IF A SALE OR TRANSFER OF THIS SECURITY OR ANY BENEFICIAL INTEREST HEREIN IS MADE IN CONTRAVENTION OF THE PRECEDING PARAGRAPH, THE ISSUER OF THIS SECURITY MAY REQUIRE SUCH TRANSFEREE TO TRANSFER THIS SECURITY OR THE APPLICABLE BENEFICIAL INTEREST HEREIN TO A PERSON THAT WOULD HAVE BEEN A PERMITTED TRANSFEREE OF SUCH TRANSFEREE’S TRANSFEROR. IF THE OBLIGATION TO TRANSFER DESCRIBED IN THE PRECEDING SENTENCE IS NOT MET, THE ISSUER HEREOF IS IRREVOCABLY AUTHORIZED, WITHOUT ANY OBLIGATION, TO TRANSFER THIS SECURITY OR THE APPLICABLE BENEFICIAL INTEREST HEREIN IN A MANNER CONSISTENT WITH THE RESTRICTIONS SET FORTH IN THIS PARAGRAPH AND, IF THIS SECURITY OR SUCH BENEFICIAL INTEREST HEREIN IS SOLD, THE ISSUER HEREOF SHALL DISTRIBUTE THE NET PROCEEDS OF SUCH SALE TO THE ENTITLED PERSON.

THIS SECURITY IS NOT A DEPOSIT, BANK ACCOUNT OR OBLIGATION OF ANY BANK. THIS SECURITY IS NOT INSURED BY THE FEDERAL DEPOSIT INSURANCE CORPORATION OR ANY OTHER AGENCY, AND IS SUBJECT TO INVESTMENT RISK, INCLUDING POSSIBLE LOSS OF PRINCIPAL.”

6. Miscellaneous.

a.  Successors and Assigns. Except as otherwise provided in this Agreement, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, or obligations under or by reason of this Agreement, except as expressly provided herein.

b.  Governing Law. This Agreement shall be governed by and construed under the laws of the State of Delaware without regard to conflict of laws principles.

c.   Counterparts; Signatures. This Agreement is intended to be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterpart signature pages to this Agreement may be delivered by Docusign, .pdf and/or electronic transmission.

d.   Notices. Unless otherwise provided, any notice, request, or other communication shall in writing and shall be given by personal delivery, national overnight courier, by certified or registered United States mail, postage prepaid to the addresses or to the email address set forth on the signature page hereof. In case of service by mail, notices shall be deemed complete at the expiration of the second business day after mailing.

e.   Amendments and Waivers. Except as otherwise provided herein, any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the holders of at least 51% of the outstanding principal amount due under the Notes. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any securities purchased under this Agreement at the time outstanding, each future holder of all such securities, and the Company.

f.   Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of this Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.

g.   Exculpation Among Investors. Each Investor acknowledges that such Investor is not relying upon any person, firm or corporation, other than the Company and its officers and directors, in making its investment or decision to invest in the Company. Each Investor agrees that no other Investor, nor the respective controlling persons, officers, directors, partners, agents or employees of any other Investor shall be liable for any action heretofore or hereafter taken or omitted to be taken by any of them in connection with sale, issuance and enforcement of the Notes.

h.   Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement among the parties and no party shall be liable or bound to any other party in any manner by any warranty, representation, or covenant except as specifically set forth herein.

IN WITNESS WHEREOF, the parties hereto have executed this Note Purchase Agreement as of the date first above written.

Bioxytran, Inc.

By:

The undersigned hereby acknowledges and agrees to become party to and to succeed to all of the rights and obligations of an “Investor” under the Note Purchase Agreement. By execution hereof, the undersigned hereby authorizes the Company to append this signature page as a counterpart signature page to the Note Purchase Agreement.

PRINCIPAL BALANCE:                                                                                                                        

INVESTOR:

Individual:

Print Name:

Entity:

(name of entity)

By:

Name:

Title:

Investor Signature Page to Note Purchase Agreement

EX-99.1

Exhibit 99.1

Copyright © Bioxytran 2022. All rights. Version 2.01.01 MIKE SHEIKH | mike.sheikh@bioxytraninc.com | (509) - 991 - 0245 Corporate Overview

Copyright © Bioxytran 2022. All rights. Version 2.01.01 Forward Looking Statement This Descriptive Presentation (the “Presentation") has been prepared by Bioxytran, Inc (the “Company”) and recipients are not entitled to rely on the accuracy or completeness of the Presentation . Statistical information contained in this Presentation is based on information available to the Company that the Company believes is accurate . It is generally based on publications that are not produced for the purposes of securities offerings or economic analysis . The Company has not reviewed or included data from all sources and cannot assure prospective parties of the accuracy or completeness of the data included in this Presentation . Forecasts and other forward - looking information obtained from these sources are subject to the same qualifications and the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance of products and services . The Company undertakes no obligation to update forward looking information to reflect actual results or changes in assumptions or other factors that could affect those statements . This Presentation has not been filed or reviewed by the Securities and Exchange Commission (“SEC”) or any securities regulatory authority of any state, nor has the SEC or any such authority passed upon the accuracy or adequacy of this Presentation . This Presentation does not constitute an offer to sell or solicitation of an offer to buy any securities . This Presentation does not purport to contain all information which may be material to a prospective party, and recipients of this Presentation should conduct their own independent evaluation and due diligence of the Company . Each recipient agrees, and the receipt of this Presentation serves as an acknowledgment thereof, that if such recipient determines to engage in a transaction with the Company, its determination will be based solely on the terms of the definitive agreement relating to such transaction and on the recipient’s own investigation, analysis and assessment of the Company and the transaction . The Company does not intend to update or otherwise revise this Presentation following its distribution . 2

Copyright © Bioxytran 2022. All rights. Version 2.01.01 3 Mission Statement Bioxytran is a clinical stage pharmaceutical company developing platform technologies in the fields of Glycovirology, Hypoxia and Degenerative Diseases to eliminate viruses and prolong lifespan using carbohydrate drug design. GLYCOVIROLOGY HYPOXIA DEGENERATIVE DISEASES

Copyright © Bioxytran 2022. All rights. Version 2.01.01 Virology: • Covid - 19 • Influenza • Other virologic diseases Long term symptoms resulting from viral infections (long - hauler): • ARDS • Pulmonary Fibrosis Technology Overview ProLectin Rx – Glycovirology BXT - 25 – Hypoxia & Degenerative Diseases Ischemia: • Stroke • Alzheimer • Dementia • Traumatic Brain Injury Anemia Wound healing ProLectin - M is a licensed technology that targets COVID - 19 mild to moderate cases MDX - viewer is a licensed technology that uniquely allow the company to prove oxygen delivery to tissue. It will be used in clinical trials as a regulatory end - point 4 Oncology and Fibrosis • Cancer Metastasis • NASH • Other Fibrotic condition Platform Overlap

Copyright © Bioxytran 2022. All rights. Version 2.01.01 ProLectin Rx Glycovirology Version 2.01.01 5

Copyright © Bioxytran 2022. All rights. Version 2.01.01 New mutations Alpha, Delta, Omicron, ? Variants are complicating the vaccination strategy If herd immunity is unattainable Therapeutic treatments are the ONLY fall back position 80% Herd Immunity 80% level has not been reached World Population Vaccination Not everyone wants to get vaccinated Not everyone has access to vaccines Lower risk of death At risk population Minimize asymptomatic spread not likely to spread without showing symptoms Vaccinations Unknowns (risks) • Duration of protection • Effectiveness against variants • Frequency of boosters • Long Term consequences of Immune system 6 Lingering Effects of COVID - 19 Version 2.01.01

Copyright © Bioxytran 2022. All rights. Version 2.01.01 ProLectin - Rx Galectin Antagonists First line of defense against all mutations of Covid - 19 STATUS: SWIFT approval pathway - Phase 3 Ready Universal Universal pandemic therapeutic Tested Complete elimination of mild to moderate cases (phase I/II clinical trials) No limitation No exclusions for age or underlying medical conditions Efficient Eliminate contagion 7

Copyright © Bioxytran 2022. All rights. Version 2.01.01 Treatment ProLectin - M Oral ProLectin - I Intravenous ProLectin - A Intravenous ProLectin - F Intravenous Combination MDX - Viewer End - to - End Solution Stage IV (long hauler) Fibrosis Elevated Galectin - 3 ~20 days ARDS Viral response 8

Copyright © Bioxytran 2022. All rights. Version 2.01.01 9 0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 3 5 7 Viral Load (Log10(average(N1+N2) Copies/mL)) Time (days) Viral Load Vs. Time ProLectin - M Treated Patients PL-CIM-002 PL-CIM-004 PL-CIM-005 PL-CIM-008 PL-CIM-009 1 Galectin Antagonist use in Mild Cases of SARS - CoV - 2; Pilot Feasibility Randomised, Open Label, Controlled Trial (longdom.org) N1+N2 Copies/mL Day 1 3 5 7 PL - CIM - 002 137080 6970 13180 16340 PL - CIM - 004 4468590 101170 9660 510 PL - CIM - 005 159730 15630 410 600 PL - CIM - 008 N/A 2268630 60180 4890 PL - CIM - 009 N/A 2154530 783750 563430 Patient 9 appeared to be an anomaly. Additionally, Patient 8 had no PCR measurement of viral load on day 1, so day 1’s PCR measurement was assumed to equal day 3’s measurement. < 50 copies/ ul Patients Treated With ProLectin - M Experienced Reductions In Viral Load Source; Phase 1 Trial 1

Copyright © Bioxytran 2022. All rights. Version 2.01.01 10 Viral Curve Comparison 1 A quantitative model used to compare within - host SARS - CoV - 2, MERS - CoV, and SARS - CoV dynamics provides insights into the pathogen esis and treatment of SARS - CoV - 2 (plos.org) 2 Galectin Antagonist use in Mild Cases of SARS - CoV - 2; Pilot Feasibility Randomised, Open Label, Controlled Trial (longdom.org) Historical control is taken from a mathematical model using longitudinal data across four different studies of symptomatic, untreated cases 1 Assumed symptom onset at a viral load of 6500 copies/mL (i.e. log10(3.81)) 1 Patients treated within 2 days of symptom onset (average 1.80 days) 2 Upper and lower bounds of the model are 95% confidence interval 1 0 1 2 3 4 5 6 0 2 4 6 8 10 Viral Load (Log10(average(N1+N2) Copies/mL)) Normalized Time (days) Viral Load Vs. Time ProLectin - M Vs. SARS - CoV - 2 Historical Control Average Untreated Average Treated Symptom Onset Randomization Patients With Day 1 Measurement < 50 copies/ul

Copyright © Bioxytran 2022. All rights. Version 2.01.01 ProLectin - M Treatment Results in SARS - CoV - 2 Spike Protein Specific Antibody Immunity Introducing Post Infection Immunization ProLectin – M clears the blood of viral load thereby reducing the strain on the Innate immune system so the Adaptive immune system can build a robust response toward future infection. 11

Copyright © Bioxytran 2022. All rights. Version 2.01.01 Galectin Inhibitor Tags Virus For Elimination Copyright © Bioxytran 2022. All rights. 12 Theoretical Mechanism of Action Liver Filtration Galectin Inhibitor Virus Human Cells Version 2.01.01

Copyright © Bioxytran 2022. All rights. Version 2.01.01 https:// www.longdom.org /abstract/galectin - antagonist - use - in - mild - cases - of - sarscov2 - pilot - feasibility - randomised - open - label - controlled - trial - 61087.html Clinical Research 13 Version 2.01.01

Copyright © Bioxytran 2022. All rights. Version 2.01.01 Proposed Phase 3 Clinical Trial Design Phase 3 Clinical Trial • 408 participants • Double Blind Randomized Controlled Trial (DBRCT) • Change in seropositivity at day 14 • Broad inclusion criteria (Vaccination status irrelevant) 14 Version 2.01.01

Copyright © Bioxytran 2022. All rights. Version 2.01.01 Product Indication Discovery Preclinical Phase I Phase II Phase III Phase IV ProLectin - M Oral Virology – Mild to Moderate • Covid - 19 • Influenza • Other virologic diseases ProLectin - I Intravenous Virology – Severe cases • Covid - 19 • Influenza • Other virologic diseases ProLectin - A* + Oxysense Intravenous combination treatment ARDS resulting from viral infection ProLectin - F* Intravenous Oncology and Fibrosis: • Cancer Metastasis • Pulmonary Fibrosis • NASH • Other Fibrotic conditions Glycovirology Development Pipeline 15 Completed Planned

Copyright © Bioxytran 2022. All rights. Version 2.01.01 Vaccines Immunomodulatory Oxygenation (Ventilators) Regenerative Medicine (Stemcells) ProLectin - Rx □ Unique Galectin Antagonist – Oral/IV Polysaccharide □ It’s not a vaccine, nor an antiretroviral drug Antiretrovirals ( Compete for polymorphism) Therapeutic Approaches for COVID - 19 Version 2.01.01 16 16

Copyright © Bioxytran 2022. All rights. Version 2.01.01 17 Competitive Landscape Oral COVID - 19 Therapeutics Drug Company Description Gov. Award Clinical stage Molnupiravir Merck Mutagenesis via RdRp – forced mutations induced apoptosis $2.2 billion EUA Paxlovid Pfizer 3CL protease inhibitor – Antiviral & Immune sensitization; Ritonovir – inhibitor enhancer $5.3 billion EUA Tollovir Todos Medical 3CL protease inhibitor – Antiviral & Anti - Cytokine activity n/a Phase 2/3 Tempol Adamis RNA - dependent RNA Polymerase (RdRp) via antioxidant & Anti - Cytokine activity n/a Phase 2/3 ProLectin - M Bioxytran Galectin antagonist – Entry Inhibitor n/a Phase 3

BXT - 25 – Hypoxia & Degenerative Diseases 18 18 Version 2.01.01

Copyright © Bioxytran 2022. All rights. Version 2.01.01 The Brain Stroke Epidemic A Challenge to Worldwide Healthcare, a $500 Billion Medical Indication Costs 19 Region Strokes Population Survivors Direct cost Indirect cost US 0.8 million 330 million 5.8 million $44 billion $22 billion EU (+GB) 1.1 million 515 million 3.4 million $28 billion $16 billion CN 2.5 million 1,402 million 7.5 million estimated $74 billion World (total) 12.2 million 7,700 million 33.0 million estimated $500 billion Global, regional, and national burden of stroke and its risk factors, 1990 – 2019: a systematic analysis for the Global Burden of Disease Study 2019 The Lancet Neurology, Vol 20, Issue 10, October 01, 2021

Copyright © Bioxytran 2022. All rights. Version 2.01.01 The Golden Hour Dilemma 20 Time to Needle 2.5 hours Equivalent to 9 Years of Aging* Onset of symptoms Ambulance arrives at home Arrival and initial assessment and treatment in ER Thombolysis or PTCA/CABG Blockage Removed * Time Is Brain — Quantified, Jeffrey L. Saver, Stroke. 2006;37:263 – 266

Copyright © Bioxytran 2022. All rights. Version 2.01.01 21 Solution: BXT - 25 an Oxygen Bridge • BXT - 25 is a hemoglobin - based polymer; 5,000 times smaller than a red blood cell • It can be used both in Ischemic and Hemorrhagic Stroke • It can penetrate a blood - clot and reach the brain within 3 minutes • Reduction of average Time - to - Needle by 90% BXT - 25 polymer Version 2.01.01

Copyright © Bioxytran 2022. All rights. Version 2.01.01 Copyright © Bioxytran 2022. All rights. Version 2.01.01 22 How It Works? BXT - 25 – Stabilized Oxygen - carrying Protein Erythrocyte Hemoglobin Heme Single O 2 molecule • Delivered as an IV solution • Universally compatible with all blood types • Non - immunogenic • Low viscosity • Stable at room temperature • 3 - year shelf - life in liquid formulation • Extended shelf - life in dry formulation

Copyright © Bioxytran 2022. All rights. Version 2.01.01 Proprietary Manufacturing Process of BXT - 25 Collect controlled source Red blood cells Extract Hemoglobin Protein Purify and crosslink Extract Heme and reattach to a polymer BXT - 25 is mixed with a saline solution, to be IV - infused by an ER team Key Assays for BXT - 25 chemical and structural specifications are: Electron spray Ionization, Amino Acid Analysis, Gel Electrophoresis, Circular Dichroism, Reverse phase HPLC and Immunoblotting 23

Copyright © Bioxytran 2022. All rights. Version 2.01.01 Proof of Concept of BXT - 25 in Animals Middle Cerebral Artery Blockage Model in Rats 24 Hypoxic area Absence of nitric oxide scavenging, no increased blood pressure in diabetic mice (Harvard Medical School, 2013) No toxicity from replacing 90% of the blood in dogs with similar chemistry to BXT - 25: (QTest Labs, Columbus OH, 2014) Oxygen delivery and brain recovery in stroke induced rats with similar chemistry to BXT - 25 (Harvard Medical School, 2013) https://www.hindawi.com/journals/ccrp/2014/864237/

Copyright © Bioxytran 2022. All rights. Version 2.01.01 Limited Effective Treatment Options Our competition is tPA and similar drugs, aiming to dissolve, or remove, a clot. These are time - consuming and require an MRI since blood - thinners are fatal in hemorrhagic strokes. THERE ARE NO DRUGS AVAILABLE TO DELIVER OXYGEN TO THE BRAIN BXT - 25 is designed to support the oxygenation of the brain until the clot is dissolved by medication or removed by surgery Drug Company Description rtPA Genentech, Johnson & Johnson Thrombolytic agent used to break apart blood clot that causes ischemic stroke Abciximab Eli Lilly /Centrocor Platelet aggregation inhibitor Cerovive AstraZeneca Nitrone based neuro protectant Candesartan AstraZeneca Angiotensin receptor blocker (ARB) Ancrod Knoll Pharmaceuticals Anticoagulant that acts by breaking down fibrinogen 25

Copyright © Bioxytran 2022. All rights. Version 2.01.01 How Do We Measure Tissue Oxygen Level? Version 2.01.01 26

Copyright © Bioxytran 2022. All rights. Version 2.01.01 FDA Approved Companion Diagnostics OXYSENSE - A clinical end - point for measuring oxygen delivery to the brain in real - time Flat probe Treated Aneurysm Tissue/brain monitored parameters Mitochondrial NADH (ATP) Hb Saturation (O 2 ) Cerebral Blood Flow Tissue Reflectance 90 Brain metabolic score Tissue metabolic score Measures real time tissue oxygenation levels Assists in determining organ viability 27

Copyright © Bioxytran 2022. All rights. Version 2.01.01 Degenerative Disease/Hypoxia Development Pipeline Treatment/Device Indication Discovery Preclinical Phase I Phase II Phase III Phase IV BXT - 101 Cancer Metastasis BXT - 102 NASH • Cirrhosis • Fibrosis BXT - 251+ Oxysense Organ Transplantation • Preservation agent • Organ monitoring BXT - 25 Stroke • Ischemic • Hemorrhagic BXT - 252 Wound Healing BXT - 253 Anemia BXT - 255 Traumatic Brain Injury 28 Completed Planned

Business Development & Strategy 29 29 Version 2.01.01

Copyright © Bioxytran 2022. All rights. Version 2.01.01 Clinical Trial Strategy 2021 2022 Product Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 ProLectin - M ProLectin - I ProLectin - F ProLectin - A / BXT - 25 Phase I/II Pre - clinical Development Phase I/II Phase III 30 Pre - clinical Development Pre - clinical Development Pre - clinical Development Phase III Phase III Phase I/II Phase I/II

Copyright © Bioxytran 2022. All rights. Version 2.01.01 Business Strategy Business Development Strategy • Collaboration agreement with qualified partner’s • Out - license agreements with Big Pharma Intellectual Property (IP) • One issued US patent (US6245316B1) • Two international patents pending approval • Additional applications to strengthen our IP position are ongoing 31

Copyright © Bioxytran 2022. All rights. Version 2.01.01 • Johnson & Johnson – Oncology, Neuroscience, Immunology, Cardiovascular, Vaccines, HIV • Roche Holdings – Oncology, Neuroscience, Immunology, Hematology, Ophthalmology • Pfizer – Oncology, Neuroscience, Cardiovascular, Diabetes • Novartis – Oncology, Neuroscience, Immunology, Cardiovascular, Respiratory, Ophthalmology • Merck – Oncology, Neuroscience, Immunology, Cardiovascular, Respiratory, Diabetes, Vaccines • Sanofi Aventis – Oncology, Neuroscience, Immunology, Inflammation, Diabetes, Vaccines • AbbVie – Oncology, Neuroscience, Immunology, Virology • GlaxoSmithKline – Oncology, Immunology, Respiratory, HIV, Vaccines • Eli Lilly – Oncology, Neuroscience, Immunology, Diabetes, Pain • Gilead – Oncology, Respiratory, Hematology, Inflammation, HIV • Bristol Meyers Squibb – Oncology, Immunology, Cardiovascular, Hematology, Inflammation • Allergan – Neuroscience, Ophthalmology, Gastroenterology • AstraZeneca – Oncology, Cardiovascular, Respiratory • Biogen – Oncology, Neuroscience, Inflammation, Stroke , Pain • Amgen – Oncology, Cardiovascular, Hematology, Inflammation Virology Oncology Immunology Respiratory Inflammation Neuroscience Cardiovascular Hematology Stroke IDEAL PLATFORM DRUG FOR MANY BIG PHARMAS THERAPEUTIC AREAS Big Pharma Licensing Targets 32 Copyright © Bioxytran 2022. All rights. Version 2.01.01

Copyright © Bioxytran 2022. All rights. Version 2.01.01 Use of Proceeds Current Round – S - 1     ProLectin - M   ProLectin - I     ProLectin - F     ProLectin - Rx* Estimated Project Cost in thousands USD*   $ 2,700     $ 1,650     $ 1,000     $ 5,350 Development & GLP     -       -       -       - Pre - Clinical     100       150       150       400 IND Submission     150       200       200       550 Clinical Trials     2,000       1,000       500       3,500 G&A     450       300       150       900 End Point     Phase III       Phase II/a       Phase II/a       Total * $2.6 million have previously been spent on proof - of - concept and GMP manufacturing of   ProLectin - M, - I, and - F Future Round     ProLectin - A   BXT - 25     Total Upcoming*     Estimated Project Cost in thousands USD*   $ 10,000     $ 10,000     $ 20,000     Development & GLP     3,150       3,150       6,300     Pre - Clinical     1,200       1,200       2,400     IND Submission     300       300       600     Clinical Trials     4,000       4,000       8,000     G&A     1,350       1,350       2,700     End Point     Phase II/a       Phase II/a       Total     33

Copyright © Bioxytran 2022. All rights. Version 2.01.01 Management David Platt PhD, CEO, CSO, Chairman Carbohydrate chemistry expert, founded four publicly traded companies, raised $150m in public markets, created $1B in shareholder value, and led development of two drugs. Ola Soderquist CPA, MSA, MBA, CFO >30 years multi - industry financial experience. Mike Sheikh, EVP BD >10 years of business development in life sciences. Broker and Research Analyst. Veronika Tyukova MBA, PM Dir >15 years of PM in Hi - Tech, Manufacturing and Commercialization. Board of Directors Anders Utter MBA, Director Audit Committee Chair, >25 years of managerial finance and accounting in medical devices and manufacturing. Dale Conaway DVM, Director Veterinary Medical Officer, Federal Research. Alan Hoberman PhD, Director Executive Director of Site Operations and Toxicology at Charles River Laboratories. Hana Chen - Walden MD, Director >30 years experience in pharmaceutical regulatory affairs in US and Europe . Advisory Board Avraham Mayevsky PhD, Professor Emeritus Worldwide authority in the field of minimal invasive monitoring of tissue and organ physiology; and professor at the Faculty of Life Sciences, Bar - Ilan University, Israel. Alben Sigamani, MD Professor and Head of Clinical Research Narayan Health, Bangalore. >17 years of experience in clinical research Thomaskutty Alumparambil, C.C.P > 30 years of clinical experience that includes heart, lung, and liver transplants. The Team 34

Copyright © Bioxytran 2022. All rights. Version 2.01.01 Copyright © Bioxytran 2021. All rights. Bioxytran, Inc. 75 2 nd Ave., Suite 605 Needham MA, 02494 (617) - 454 - 1199 www.bioxytraninc.com info@bioxytraninc.com Mike Sheikh mike.sheikh@bioxytraninc.com (509) - 991 - 0245 Version 2.01.01

XML

Cover	Jan. 05, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jan. 05, 2022
Entity File Number	001-35027
Entity Registrant Name	BIOXYTRAN, INC.
Entity Central Index Key	0001445815
Entity Tax Identification Number	26-2797630
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	75, Second Avenue,
Entity Address, Address Line Two	Suite 605
Entity Address, City or Town	Needham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02494
City Area Code	(617)
Local Phone Number	494-1199
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001
Trading Symbol	BIXT
Entity Emerging Growth Company	false